SLU-PP-332

ID: slupp332

Aliases: SLU-PP332, pan-ERR agonist, SLU-PP-332

Type: compound

Route/form: oral or route depends on studied product

Status: research

Evidence level: preclinical

Best data tier: non-human experimental

Support scope: non-human/mechanistic

Source types: preclinical

Linked sources: 5

Broad outcomes: Fat loss / metabolic health, Longevity / mitochondrial / redox, Muscle growth / performance / recovery

Reading note: These are curation notes anchored to linked sources, not a clinical recommendation or protocol.

Targets / mechanism

• ERR alpha agonist
• ERR beta agonist
• ERR gamma agonist

Optimization domains

• exercise mimetic
• mitochondrial
• metabolic

Research basis

• SLU-PP-332 has direct preclinical data for ERR-dependent aerobic-exercise-response transcription, oxidative skeletal-muscle fiber shifts, endurance, and metabolic-syndrome models.
• Follow-on oral ERR agonist work with SLU-PP-915 supports the target class as an exercise-mimetic research program rather than a single isolated screening hit.
• The mechanism is relevant to mitochondrial and fatty-acid oxidation discussions because ERRs regulate oxidative metabolism programs.

Limits, risks, and missing evidence

• There is no controlled human efficacy evidence for fat loss, endurance, or muscle gain.
• It is a small-molecule ERR agonist, not a peptide, and non-human exercise-mimetic data should not be read as exercise replacement.
• Dosing, tissue selectivity, long-term safety, and off-target pharmacology remain unresolved.

Risk flags

• unapproved context
• preclinical only

Linked papers, labels, and reviews

1. Synthetic ERR alpha/beta/gamma agonist induces an acute aerobic exercise response
   preclinical / pubmed_slupp332_2023
   SLU-PP-332 mouse and cell work.
2. A synthetic ERR agonist alleviates metabolic syndrome
   preclinical / pubmed_slupp332_metabolic_syndrome_2024
   SLU-PP-332 preclinical metabolic-syndrome model; adjacent to exercise-mimetic and fat-oxidation rationale.
3. Chemical optimization of the exercise mimetic SLU-PP-332
   preclinical / sciencedirect_slupp332_sar_2026
   2026 SAR paper.
4. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
   preclinical / pubmed_slupp915_exercise_2026
   Orally active pan-ERR agonist follow-on to SLU-PP-332; useful class/mechanism context, still non-human efficacy.
5. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function
   preclinical / pubmed_panerr_agonists_heart_failure_2024
   ERR agonist tissue-metabolism context; supports mitochondrial/fatty-acid oxidation mechanism but not human enhancement use.